1850 North Gravers Road offers a flexible available layout for a myriad of space configurations and uses. The property is strategically located in the heart of Plymouth Meeting at the Mid-County Interchange, the intersection of I-276 and I-476 with visibility to over 67,000 vehicles per day.
Project improvements will include new exterior facade and canopies, new building and monument signage, generator connectivity, and improved natural lighting with an optional window package for tenant selection.
Neighboring corporations include:
PHILADELPHIA’S NEWEST SUBURBAN BIOTECH OPPORTUNITY
OWNERSHIP:
Founded in 1966, Spaulding and Slye Investments has a proven track record of successful investments nationwide with a strategic focus in life science real estate within the Mid-Atlantic and New England markets. SSI presents a deep resume of permitting, developing, repositioning and leasing life science assets including laboratory/R&D, GMP manufacturing, and flex/R&D. Since 2000, SSI has acquired, entitled and developed approximately 1 million square feet of life science product, outperforming our tenants’ and investors’ expectations. SSI’s pipeline currently includes 1.4 million square feet of potential new development and acquisitions, including a substantive focus in the Philadelphia region.
PROJECT TEAM:
South Duvall is a commercial real estate investor based out of Rockville, MD focusing on value-add properties and select stabilized properties. Founded in 2017 by Robert Scheer, its principals have a two-decade track record of creating value through repositioning existing real estate assets throughout the Washington, D.C. Metro Area. While experienced in all asset classes, South Duvall is known for its expertise in Life Science, Health Care and Technology real estate.
Scheer Partners’ Scientific Real Estate Practice specializes in developing real estate solutions for companies within this industry sector. We partner with our clients to define and implement a strategy and then develop real estate solutions that best fit the company’s specific business needs and growth. Scheer Partners has built an unparalleled reputation in the biotechnology, pharmaceutical, and lab-related industries for providing innovative real estate solutions. Scheer Partners’ superior understanding of scientific facilities delivers more options to our clients, which have enabled them to achieve better transaction economics, and reduce capital costs while minimizing their out of pocket expense. Our reputation for success is proven in our track record; Scheer Partners has negotiated over 450 lab transactions, in excess of 8 million square feet.